To cure myeloma by fostering research, education and excellence in clinical care worldwide.

Scroll Down

Upcoming Events

Educational Workshop Marrakech, Morocco

June 27 - 28, 2025 - Radisson Blu Hotel, Marrakech Carre Eden

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

Program

3rd Annual Workshop on Genomics: Genomics and Translational Medicine in Myeloma

July 11 - 12, 2025 - Sheraton Lisboa, Lisbon, Portugal

The IMS Workshop on Genomics was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. Building upon this success, the Third IMS Genomics Meeting will be a public meeting led by global myeloma KOL.

The 2025 workshop will cover evolving evidence and clinical advances in myeloma, with a focus on drafting next-generation clinical studies and translational research based on data spanning multiple omics platforms and scales of resolution. The first day of the meeting will examine the state of science in myeloma precursor conditions, including SMM risk stratification and genomics of SMM/MGUS. The second day will highlight how high-throughput technological advances can inform future translational and clinical research throughout the MM disease continuum.

Preliminary Program

22nd IMS Annual Meeting

September 17 - 20, 2025 - Toronto, Canada

Mark your calendars for the 22nd IMS Annual Meeting in Toronto, Canada.

The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical, and clinical aspects.

This year’s program includes:

Four thematic sessions on:
- Precursor Disease
- Risk Adaptation Management
- Immunotherapy
- Relapse within 1-3 lines of therapy
Talks and symposia on pressing topics led by the KOL of the myeloma community
Keynote addresses
Joint sessions with regulatory agencies and other organisations
Meet the Expert sessions
Oral Abstracts (on Basic Biology, Preclinical Trials, and Clinical Studies)
Poster presentations and discussion sessions

Apply for a Translational Research Award today!

Deadline January 31, 2025

Apply for an IMS Career Development Award!

Deadline January 31, 2025

Translational Research Award

Career Development Award

IMS Young Investigator Award

COMING SOON – ARTEMIS

Meet the recipients of the IMS Translational Research Award!

Meet the recipients of the IMS Career Development Award!

About Our Publications

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

See All Publications

Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.